Ref (type) | Population | Outcome, Interventions | Results and statistical analysis | Effect size | Favours |
Adverse effects | |||||
Systematic review |
599 women with moderate to severe pain 14 RCTs in this analysis |
Adverse effects
with NSAIDs with placebo |
RR (NSAIDs [analysed as a group] v placebo) 1.29 95% CI 1.05 to 1.59 However, no significant difference between any 1 NSAID and placebo |
Small effect size | placebo |
RCT Crossover design 5-armed trial |
104 women with primary dysmenorrhoea |
Adverse effects
with ibuprofen arginate 200 mg with ibuprofen arginate 400 mg with ibuprofen 200 mg with ibuprofen 400 mg with placebo Absolute results not reported |
Reported as no significant difference between active treatments and placebo |
Not significant | |
RCT Crossover design 3-armed trial |
73 women with moderate to severe primary dysmenorrhoea |
Incidence of adverse effects
12% with etoricoxib 25% with naproxen sodium 15% with placebo Absolute numbers not reported |
Significance assessment not performed |
||
RCT Crossover design 3-armed trial |
73 women with moderate to severe primary dysmenorrhoea |
Headache
1.5% with etoricoxib 7.5% with naproxen sodium 4.5% with placebo Absolute numbers not reported |
Significance assessment not performed |
||
RCT Crossover design 3-armed trial |
73 women with moderate to severe primary dysmenorrhoea |
Nausea
3% with etoricoxib 3% with naproxen sodium 1.5% with placebo Absolute numbers not reported |
Significance assessment not performed |
||
RCT Crossover design 4-armed trial |
144 women with moderate to severe primary dysmenorrhoea |
Proportion of people reporting adverse effects
23% with naproxen 13% with placebo Absolute numbers not reported |
Significance assessment not reported |
||
RCT Crossover design 3-armed trial |
149 women aged between 18 and 44 years, with primary dysmenorrhoea |
Adverse effects
40/129 (31%) with celecoxib 46/126 (37%) with naproxen sodium 38/127 (30%) with placebo |
|||
RCT 3-armed trial |
180 women with primary dysmenorrhoea |
Adverse effects
with mefenamic acid with placebo |